Back HIV/AIDS

HIV / AIDS

IAS 2013: Raltegravir/Etravirine Dual Regimen Maintains Viral Suppression

A regimen of raltegravir (Isentress) plus etravirine (Intelence) without NRTIs or protease inhibitors was able to keep HIV in check after switching from a standard regimen if patients did not have pre-existing NNRTI resistance, researchers reported at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

alt

IAS 2013: Single Tablet Regimens Do Not Always Produce Better HIV Treatment Outcomes

One pill per day does not necessarily lead to more durable HIV suppression than regimens containing more pills taken twice-daily, according to a study presented at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

alt

IAS 2013: Acute Retroviral Syndrome Linked to HIV Disease Progression

People who reported higher scores on a scale of symptom severity during initial HIV infection had lower CD4 T-cell counts, higher viral load set-points, and greater likelihood of HIV disease progression than those with mild or no acute antiretroviral symptoms, researchers reported at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

alt

IAS 2013: Combination Prevention Trial Shows Drop in HIV Incidence, Increase in Testing

Results from Project ACCEPT, a pioneering HIV prevention trial comparing the effects of mobile HIV testing, community mobilization, and enhanced support for people with HIV, versus standard voluntary counseling and testing, were announced at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention in Kuala Lumpur.

alt

IAS 2013: Middle-income Countries Outside Africa Pay Four Times More for Antiretroviral Drugs

Middle-income countries outside Africa are paying, on average, 4 times more for antiretrovirals than African countries with similar gross national incomes (GNI), according to a study presented recently at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur.

alt

[Produced in collaboration with Aidsmap.com]

FDA Limits Use of Oral Antifungal Ketoconazole Due to Side Effects and Drug Interactions

The antifungal drug ketoconazole (brand name Nizoral), used to treat certain AIDS-related opportunistic infections, should no longer be used as first-line oral therapy for any infection due to its potential to cause liver toxicity and adrenal gland problems, and instead should be reserved for those who cannot take or do not respond to other treatments, according to the U.S. Food and Drug Administration. The warning does not apply to topical formulations.

alt

HIV+ Women May Experience More Severe Menopause Symptoms

Women with HIV on average experience more severe hot flashes around the time of menopause than HIV negative women, and they interfere more with daily life, according to a study described in the July 1, 2013, advance online edition of the journal Menopause.

alt